spacer
The Healthcare Sales & Marketing Network celebrates 25 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  colitis 

 HSMN NewsFeed - 19 Sep 2022
AbbVie Secures Positive CHMP Opinion for Risankizumab (SKYRIZI(R)) for the Treatment of Adults with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 4 Aug 2022
Amgen to Acquire Chemocentryx for $4 Billion in Cash
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 24 May 2022
Fifty Percent of Patients with Ulcerative Colitis Treated with Mirikizumab Achieved Clinical Remission at One Year in Lilly's Pivotal Phase 3 Study
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 28 Mar 2022
Protagonist Therapeutics Announces Appointment of Asif Ali as Executive Vice President and Chief Financial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 22 Dec 2021
Sorriso Pharmaceuticals Launches with $31 Million to Develop Novel Class of Orally Delivered Cytokine Antibodies to Treat Inflammatory Conditions
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 18 Oct 2021
FDA Approves Cyltezo, the First Interchangeable Biosimilar to Humira
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 14 Oct 2021
Immunic, Inc. Appoints Patrick Walsh as Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Sep 2021
Protagonist Therapeutics Appoints Scott Plevy, M.D., Executive Vice President and Therapeutic Head, Gastroenterology
Biopharmaceutical Gastroenterology Personnel
 HSMN NewsFeed - 24 Aug 2021
European Commission Approves RINVOQ(R) (upadacitinib) as First JAK Inhibitor in the European Union for the Treatment of Both Adults and Adolescents with Moderate to Severe Atopic Dermatitis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 24 Aug 2021
InDex Pharmaceuticals receives FDA clearance to start the phase III study CONCLUDE with cobitolimod
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 17 Aug 2021
Lilly Announces Leadership Changes and Formation of Neuroscience and Immunology Business Units
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Feb 2021
Avexegen Therapeutics Receives a $2.94M NIH Grant to Advance Treatment for Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 12 Feb 2021
The Lancet Publishes Libtayo(R) (cemiplimab) Data Showing Extended Overall Survival in Patients with First-line Advanced Non-small Cell Lung Cancer with PD-L1 Expression of ≥50%
Biopharmaceuticals Oncology
 HSMN NewsFeed - 26 Jan 2021
Connect Biopharma Strengthens Leadership Team with Key Hire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jan 2021
Sebela Pharmaceuticals Announces U.S. Launch of SUTAB(R) Tablets, An Alternative to Liquid Colonoscopy Preparation
Biopharmaceuticals Gastroenterology FDA Product Launch
 HSMN NewsFeed - 22 Dec 2020
Soligenix Announces Topline Results from its Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology
 HSMN NewsFeed - 11 Dec 2020
BAVENCIO(R) (avelumab) Receives Positive CHMP Opinion for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 11 Dec 2020
CHMP Recommends the Approvals of RINVOQ(TM) (Upadacitinib) for the Treatment of Adults with Active Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Nov 2020
Innovent Announces NMPA Granted New Indication Approval for SULINNO(R) (Adalimumab Injection) in China for the Treatment of Polyarticular Juvenile Idiopathic Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Nov 2020
FDA grants Emergency Use Authorisation for baricitinib in hospitalised COVID-19 patients nine months after initial hypothesis was published by BenevolentAI
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Nov 2020
Athos Therapeutics Announces Appointment of Chief Business Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Sep 2020
Innovent Announces NMPA Granted Marketing Approval for SULINNO(R) (Adalimumab Injection) in China
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Aug 2020
Connect Biopharma Completes $115 Million Series C Financing to Advance Ongoing Clinical Trials in Atopic Dermatitis and Ulcerative Colitis and Initiate Additional Clinical Programs
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 17 Jul 2020
Lilly's Mirikizumab Superior to Cosentyx(R) (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 26 Jun 2020
Janssen Announces Discontinuation of Phase 3 LOTUS Study Evaluating Ustekinumab in Systemic Lupus Erythematosus
Biopharmaceuticals
 HSMN NewsFeed - 18 Jun 2020
Almirall Announces FDA Approval Of Updated Label For Seysara(R) (Sarecycline) Tablets
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 1 Jun 2020
Lilly's Taltz(R) (ixekizumab) is the First IL-17A Antagonist to Receive U.S. FDA Approval for the Treatment of Non-Radiographic Axial Spondyloarthritis (nr-axSpA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Apr 2020
ANI Receives Refusal to File Letter from FDA for Cortrophin(R) Gel
Biopharmaceuticals FDA
 HSMN NewsFeed - 9 Apr 2020
EMD Serono and Pfizer Receive US FDA Breakthrough Therapy Designation and Submit Application for BAVENCIO(R) for First-Line Maintenance Treatment of Locally Advanced or Metastatic Urothelial Carcinoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 30 Mar 2020
Lilly's Taltz(R) (ixekizumab) Receives U.S. FDA Approval for the Treatment of Pediatric Patients with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 13 Mar 2020
EMD Serono and Pfizer Provide Update on Phase III JAVELIN Head and Neck 100 Study
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jan 2020
Bioniz Therapeutics enters into an option agreement for acquisition by Almirall of its lead clinical candidate BNZ-1 in development for immuno-dermatologic and onco-dermatologic diseases
Biopharmaceuticals Dermatology Mergers & Acquisitions
 HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents 52-Week Head-to-Head (SPIRIT-H2H) Data from Taltz(R) (ixekizumab) Versus Humira(R) (adalimumab) Trial in Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 12 Nov 2019
ACR 2019: Lilly Presents Positive New Data from COAST-X, a Phase 3 Study of Taltz(R) (ixekizumab) in Patients with Non-Radiographic Axial Spondyloarthritis
Biopharmaceuticals
 HSMN NewsFeed - 5 Nov 2019
Regeneron Provides Updates on Phase 3 Libtayo(R) (cemiplimab) Development Program in Advanced Non-small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 18 Oct 2019
AbbVie Receives CHMP Positive Opinion for Upadacitinib (RINVOQ(TM)) for the Treatment of Adults with Moderate to Severe Active Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 3 Oct 2019
New Head-to-Head Data Show Taltz(R) (ixekizumab) Superiority versus TREMFYA(R) (guselkumab) in People with Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 26 Aug 2019
Lilly Receives U.S. FDA Approval for Taltz(R) (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Aug 2019
Lilly Launches Open Innovation Challenge to Help Transform Inflammatory Bowel Disease (IBD) Care through Digital Health
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 1 Aug 2019
Nektar Therapeutics and Bristol-Myers Squibb Announce U.S. FDA Breakthrough Therapy Designation for Bempegaldesleukin (NKTR-214) in Combination with Opdivo(R) (nivolumab) for the Treatment of Patients with Untreated Advanced Melanoma
Biopharmaceuticals Oncology
 HSMN NewsFeed - 14 Jun 2019
Janssen reports top-line Phase 3 results for TREMFYA(R) (guselkumab) in adults with active psoriatic arthritis
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2019
Lilly Presents Positive Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis at the European Congress of Rheumatology
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2019
Lilly to Present 5-Year Sustained Efficacy and Safety Results for Taltz(R) (ixekizumab) in Patients with Plaque Psoriasis at the World Congress of Dermatology
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 6 Jun 2019
Palatin Technologies Granted FDA Orphan Drug Designation -- PL-8177 for the Treatment of Non-Infectious Uveitis
Biopharmaceuticals Ophthalmology FDA
 HSMN NewsFeed - 2 Apr 2019
Provention Bio Announces Key Additions to its Senior Management Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Mar 2019
Allergan Announces FDA Approval of AVYCAZ(R) (ceftazidime and avibactam) for Pediatric Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Mar 2019
RDD Pharma Appoints John Temperato as Chief Executive Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 13 Mar 2019
Alvotech Enrolls First Patient in Clinical Phase III Study Involving Biosimilar Version of HUMIRA(R)
Biopharmaceuticals Generics Dermatology
 HSMN NewsFeed - 4 Mar 2019
Important New Trial With Oral FERACCRU(R) Shows Comparable Efficacy to IV Iron (Ferric Carboxymaltose), Offering a Real Alternative to Hospital Administration for Many Patients[4]
Biopharmaceuticals
 HSMN NewsFeed - 1 Mar 2019
AbbVie Receives CHMP Positive Opinion for Risankizumab (SKYRIZI(TM)) for the Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 19 Feb 2019
AbbVie Announces New Drug Application Accepted for Priority Review by U.S. FDA for Upadacitinib for Treatment of Moderate to Severe Rheumatoid Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Dec 2018
Lilly Announces Positive Top-Line Results for Taltz(R) (ixekizumab) vs. Humira(R) (adalimumab) in a Head-to-Head (SPIRIT-H2H) Superiority Study in Patients with Active Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 19 Nov 2018
FDA Approves AEMCOLO(TM) (rifamycin), the First Antibiotic Approved for the Treatment of Travelers' Diarrhea in Over a Decade
Biopharmaceuticals FDA Product Launch
 HSMN NewsFeed - 19 Nov 2018
Merck KGaA, Darmstadt, Germany, and Pfizer Provide Update on Avelumab in Platinum-Resistant/Refractory Ovarian Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 24 Oct 2018
Inova Diagnostics Launches First FDA Cleared Calprotectin Extraction Device
Devices Diagnostics FDA Product Launch
 HSMN NewsFeed - 13 Sep 2018
AbbVie Announces Patient-Reported Outcomes Data from Three Pivotal Phase 3 Studies of Risankizumab, Showing Significant Improvements in Health-Related Quality of Life for Patients with Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 10 Sep 2018
Lilly Announces Initiation of IXORA-R Head-to-Head Trial Comparing Taltz(R) and Tremfya(R) in Patients with Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals
 HSMN NewsFeed - 2 Jul 2018
Phase III IMpassion130 Study Showed Genentech's TECENTRIQ Plus Abraxane Significantly Reduced the Risk of Disease Worsening or Death in People With Metastatic or Locally Advanced Triple Negative Breast Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 28 Jun 2018
Lilly Announces Positive Top-Line Results for Second Phase 3 Study of Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis) for TNF Inhibitor-Experienced Patients
Biopharmaceuticals
 HSMN NewsFeed - 4 Jun 2018
RDD Pharma Appoints Dr. Mark Sirgo as Board Chairman
Biopharmaceuticals Gatroenterology Personnel
 HSMN NewsFeed - 29 May 2018
UCB Announces the Approval of CIMZIA(R) (certolizumab pegol) for Moderate-to-Severe Plaque Psoriasis, Representing an Important New Option for Patients in the U.S.
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 4 May 2018
InDex Pharmaceuticals Develops Oral Formulation of Cobitolimod
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 7 Mar 2018
New Blood Test to Accurately Detect Fibromyalgia Now Available from Data Science Company IQuity
Diagnostics Product Launch
 HSMN NewsFeed - 19 Feb 2018
AAD 2018: Treatment with Lilly's Taltz(R) (ixekizumab) Resulted in Improvement in Impact of Genital Psoriasis on Sexual Activity
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 13 Feb 2018
Lilly Announces Positive Top-Line Phase 3 Results for Taltz(R) (ixekizumab) in Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
Biopharmaceuticals
 HSMN NewsFeed - 12 Feb 2018
Ferring's CLENPIQ(TM) (sodium picosulfate, magnesium oxide, and anhydrous citric acid) Oral Solution for Colonoscopy Prep Now Available
Biopharmaceuticals Gastroenterology Product Launch
 HSMN NewsFeed - 2 Feb 2018
FDA Approves AVYCAZ(R) (ceftazidime and avibactam) for the Treatment of Patients with Hospital-Acquired Bacterial Pneumonia and Ventilator-Associated Bacterial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jan 2018
Novartis new data reinforces superiority of Cosentyx(R) versus Stelara(R) in achieving skin clearance for psoriasis patients
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 3 Jan 2018
Inova Diagnostics Receives FDA Clearance for the First Fully Automated, Random Access Calprotectin Test
Diagnostics FDA
 HSMN NewsFeed - 14 Dec 2017
Protagonist Therapeutics Appoints Sarah Noonberg, M.D., Ph.D. to the Board of Directors
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 16 Nov 2017
RDD Pharma Raises $9.5M in Series B Funding to Fuel Global Development
Biopharmaceuticals Gastroenterology Venture Capital
 HSMN NewsFeed - 8 Nov 2017
Long-Term Use of Lilly's Taltz(R) (ixekizumab) Shows Efficacy Improvements in Psoriatic Arthritis for Patients with Prior Inadequate Response or Intolerance to TNF Inhibitors
Biopharmaceuticals
 HSMN NewsFeed - 20 Oct 2017
Celgene Provides Update on GED-0301 (mongersen) Inflammatory Bowel Disease Program
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 21 Sep 2017
European Commission Approves Bavencio (avelumab) for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Jul 2017
eFFECTOR Therapeutics Completes $38.6 Million Series C Financing
Biopharmaceuticals Oncology Venture Capital Personnel
 HSMN NewsFeed - 21 Jul 2017
EMA's CHMP Issues Positive Opinion for Avelumab for the Treatment of Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 26 Jun 2017
Provention Bio, Inc. Secures $28.4 Million Founding Financing to Fund Development Targeting the Interception and Prevention of Immune-Mediated Disease
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 19 Jun 2017
Complete Efficacy and Long-Term Follow-Up Safety Results from SGX942 Phase 2 Oral Mucositis Clinical Trial to be Presented at the 2017 Multinational Association for Supportive Care in Cancer Conference
Biopharmaceuticals Oncology
 HSMN NewsFeed - 16 Jun 2017
EULAR 2017: Lilly's Taltz(R) (ixekizumab) Demonstrated No Progression or Minimal Progression of Radiographic Disease in Patients with Psoriatic Arthritis Through 52 Weeks
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2017
Arena Pharmaceuticals Appoints Jennifer Jarrett to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jun 2017
TECHLAB(R) Receives FDA 510(k) Clearance To Market E. HISTOLYTICA QUIK CHEK(TM) To Aid Clinicians In The Diagnosis Of Amebiasis Caused By The E. Histolytica Parasite
Diagnostics FDA
 HSMN NewsFeed - 8 Jun 2017
Protagonist Therapeutics Appoints Five Prime Therapeutics CEO, Lewis T. "Rusty" Williams, to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 30 May 2017
Janssen Enters Into Worldwide Exclusive License and Collaboration Agreement With Protagonist Therapeutics, Inc. for Oral Interleukin-23 Receptor Antagonist Drug Candidate for the Treatment of Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 30 May 2017
Array BioPharma and Bristol-Myers Squibb Announce Strategic Collaboration
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 May 2017
FDA Grants BAVENCIO(R) (avelumab) Approval for a Common Type of Advanced Bladder Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 3 May 2017
Soligenix Receives FDA Protocol Clearance of Pivotal Phase 3 Clinical Trial of SGX942 for the Treatment of Oral Mucositis in Head and Neck Cancer Patients
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Apr 2017
RedHill Biopharma and IntelGenx Announce Marketing Approval of RIZAPORT(R) for Migraines in Luxembourg
Biopharmaceuticals Drug Delivery Regulatory
 HSMN NewsFeed - 30 Mar 2017
U.S. FDA Approves Addition of Moderate to Severe Fingernail Psoriasis Data to AbbVie's HUMIRA(R) (adalimumab) Prescribing Information
Biopharmaceuticals FDA
 HSMN NewsFeed - 24 Mar 2017
FDA Grants Approval for BAVENCIO(R) (avelumab), the First Immunotherapy Approved for Metastatic Merkel Cell Carcinoma
Biopharmaceuticals Oncology FDA Product Launch
 HSMN NewsFeed - 15 Mar 2017
FDA Approves Merck’s KEYTRUDA(R) (pembrolizumab) for Adult and Pediatric Patients with Classical Hodgkin Lymphoma (cHL) Refractory to Treatment, or Who Have Relapsed After Three or More Prior Lines of Therapy
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 13 Mar 2017
Lycera Announces the Appointment of Pablo J. Cagnoni, M.D., to the Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Jan 2017
Immune Pharmaceuticals Appoints New Chairman of the Board of Directors
Biopharmaceuticals Gastroenterology Oncology Personnel
 HSMN NewsFeed - 20 Jan 2017
Bristol-Myers Squibb Provides Regulatory Update in First-line Lung Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Dec 2016
Health Canada approves STELARA(R) for the treatment of adults with moderately to severely active Crohn's disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 14 Nov 2016
AbbVie's HUMIRA(R) (Adalimumab) Receives CHMP Positive Opinion to Treat Adolescents with Hidradenitis Suppurativa, a Chronic Inflammatory Skin Disease
Biopharmaceuticals Dermatology Regulatory
 HSMN NewsFeed - 11 Nov 2016
Bristol-Myers Squibb’s Opdivo(R) (nivolumab) is the First Immuno-Oncology Treatment to Receive FDA Approval Based on Overall Survival in Head and Neck Cancer
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 14 Oct 2016
Bristol-Myers Squibb Receives Positive CHMP Opinion for Opdivo (nivolumab) for the Treatment of Adult Patients With Relapsed or Refractory Classical Hodgkin Lymphoma After Autologous Stem Cell Transplant and Treatment With Brentuximab Vedotin
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 3 Oct 2016
Allergan plc Enters Into Licensing Agreement with AstraZeneca to Obtain Worldwide Rights to MEDI2070 Inflammatory Disorder Development Program
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 15 Sep 2016
Teva Strengthens Injectables Portfolio with the Launch of an Authorized Generic of Cubicin(R) (Daptomycin for Injection) in the United States
Biopharmaceuticals Generics Product Launch
 HSMN NewsFeed - 12 Sep 2016
Soligenix and SciClone Establish Regional Licensing Agreement for SGX942, a Novel Product Candidate for Oral Mucositis
Biopharmaceuticals Licensing
 HSMN NewsFeed - 18 Aug 2016
FDA Grants Soligenix Orphan Drug Designation for Dusquetide for Treatment of Macrophage Activation Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Aug 2016
Arena Pharmaceuticals Announces Appointment of Vincent Aurentz as Chief Business Officer
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 8 Jul 2016
William D. Waddill, Calithera CFO, Elected to Protagonist Therapeutics Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 5 Jul 2016
Takeda and TiGenix Enter into Licensing Agreement for Ex-U.S. Rights to Cx601 for the Treatment of Complex Perianal Fistulas in Patients with Crohn's Disease
Biopharmaceuticals Regenerative Medicine Licensing
 HSMN NewsFeed - 27 Jun 2016
Merck Receives CHMP Positive Opinion for KEYTRUDA(R) (pembrolizumab) for the Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 23 Jun 2016
Allergan Announces FDA Approval of Supplemental New Drug Application (sNDA) for AVYCAZ(R) (ceftazidime and avibactam)
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Jun 2016
Merck’s KEYTRUDA(R) (pembrolizumab) Demonstrates Superior Progression-Free and Overall Survival Compared to Chemotherapy as First-Line Treatment in Patients with Advanced Non-Small Cell Lung Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 31 May 2016
Allergan Receives FDA Approval of TEFLARO(R) (ceftaroline fosamil) for Pediatric Patients
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 May 2016
FLIXABI(R), Biogen’s Infliximab Biosimilar Referencing Remicade(R), Approved in the European Union
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 May 2016
AbbVie's HUMIRA(R) (adalimumab) Receives CHMP Positive Opinion to Treat Certain Forms of Non-Infectious Uveitis, a Disease that Can Severely Impact Vision
Biopharmaceuticals Ophthalmology Regulatory
 HSMN NewsFeed - 20 Apr 2016
Second Genome Secures $42.6 Million in Series B Financing Led by Pfizer Venture Investments and Roche Venture Fund
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 20 Apr 2016
Enterome Raises EUR14.5 Million in Series C Financing Round
Biopharmaceuticals Gastroenterology Venture Capital
 HSMN NewsFeed - 4 Apr 2016
AbbVie Receives CHMP Positive Opinion for HUMIRA(R) (adalimumab) for the Treatment of Pediatric Patients, from Six Years of Age, with Moderately to Severely Active Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 29 Mar 2016
Shire Wins Patent Trial Against Watson Concerning LIALDA(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 18 Mar 2016
STELARA(R) Induced Clinical Response And Remission In Phase 3 Study For The Treatment Of Patients With Moderate To Severe Crohn's Disease Who Had Previously Failed Or Were Intolerant To Anti-TNF-Alpha Therapy
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 2 Mar 2016
Asana Medical, Inc. Names Dr. Christine V. Sapan CEO, Adds University of Miami's Sergio M. Gonzalez to Its Board of Directors
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 2 Mar 2016
Merck KGaA, Darmstadt, Germany Initiates Phase III Study of MSB11022, a Proposed Biosimilar of Adalimumab, in Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 24 Feb 2016
FDA Accepts and Grants Priority Review for AVYCAZ(R) (ceftazidime and avibactam) Supplemental New Drug Application (sNDA)
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Feb 2016
FDA Accepts Supplemental New Drug Application (sNDA) for TEFLARO(R) (ceftaroline fosamil)
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Feb 2016
Sigmoid Pharma Announces Acquisition of Freund Pharmatec Ltd.
Biopharmaceuticals Drug Delivery Mergers & Acquisitions
 HSMN NewsFeed - 1 Feb 2016
Dr. Reddy’s Laboratories Receives USFDA Tentative Approval for Zenavod(TM) (doxycycline) Capsules, 40 mg for the Treatment of Rosacea in Adults
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 21 Jan 2016
Allergan Announces FDA Approval of Updated Label for New Dosing Regimen for DALVANCE(R) (dalbavancin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Jan 2016
iCo Strategic Reorganization
Biopharmaceuticals Personnel
 HSMN NewsFeed - 21 Dec 2015
Oral REVLIMID(R) Plus Dexamethasone Granted Approval for Treatment of Patients with Newly Diagnosed Multiple Myeloma in Japan
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 10 Dec 2015
Lilly and Merck Expand Immuno-Oncology Collaboration Adding Abemaciclib and KEYTRUDA(R) Combination Trial
Biopharmaceuticals Oncology
 HSMN NewsFeed - 4 Dec 2015
Samsung Bioepis' RENFLEXIS(R) Infliximab Biosimilar Receives Regulatory Approval in Korea
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Nov 2015
European Commission Approves Reconciliation of Indications for nivolumab Under the Opdivo(R) European Marketing Authorization Application
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 24 Nov 2015
Bristol-Myers Squibb Announces U.S. Food and Drug Administration Approval for Opdivo (nivolumab) as a Single Agent for the Treatment of Patients with Previously Untreated BRAF Wild-Type Advanced Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 10 Nov 2015
Seres Therapeutics Appoints Kurt Graves to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Oct 2015
Bristol-Myers Squibb Receives Approval from the U.S. Food and Drug Administration for the Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen in BRAF V600 Wild-Type Unresectable or Metastatic Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 11 Sep 2015
AbbVie's HUMIRA(R) (Adalimumab) Receives First and Only U.S. Food and Drug Administration Approval for Moderate to Severe Hidradenitis Suppurativa
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 14 Aug 2015
Baxter and Water Street Announce FDA Approval of CEFAZOLIN 2 Gram Premix
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Aug 2015
Chiasma Expands Management Team with Announcement of Anand Varadan as Chief Commercial Officer
Biopharmaceuticals Drug Delivery Personnel
 HSMN NewsFeed - 8 Jul 2015
Synergy Pharmaceuticals Appoints Troy Hamilton as Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 May 2015
Roche receives FDA clearance for the cobas(R) Cdiff Test to detect Clostridium difficile
Diagnostics FDA
 HSMN NewsFeed - 24 Apr 2015
Bristol-Myers Squibb Receives Positive CHMP Opinion in the European Union for Opdivo (nivolumab) for the Treatment of Advanced Melanoma in Both First-Line and Previously Treated Patients
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 31 Mar 2015
GW Pharmaceuticals Initiates First Phase 3 Pivotal Trial for Epidiolex in Dravet Syndrome
Biopharmaceuticals Neurology
 HSMN NewsFeed - 24 Feb 2015
Shire Acquires Meritage Pharma
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 23 Jan 2015
The Medicines Company Receives CHMP Positive Opinions for Three Hospital Acute Care Products: KENGREXAL(TM) (cangrelor), ORBACTIV(TM) (oritavancin) and RAPLIXA(TM) (sealant powder)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 25 Nov 2014
Valeant Pharmaceuticals Announces FDA Approval Of ONEXTON(TM) Gel For The Treatment Of Acne Vulgaris
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 19 Sep 2014
European Commission Grants Marketing Authorization for Gilead’s Zydelig(R) (Idelalisib) for the Treatment of Chronic Lymphocytic Leukemia and Follicular Lymphoma
Biopharmaceuticals Oncology Regulatory
 HSMN NewsFeed - 28 Jul 2014
Aqua Pharmaceuticals, LLC Announces the U.S. Food and Drug Administration (FDA) Approval of ACTICLATE(TM) (doxycycline hyclate USP) Tablets, 150 mg and 75 mg
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Jun 2014
Protalix Announces New Data on ELELYSO(TM) (taliglucerase alfa) Presented at the European Working Group on Gaucher Disease 2014 11th Meeting
Biopharmaceuticals
 HSMN NewsFeed - 6 Jun 2014
Immune Appoints Gad Berdugo to Board of Directors and Karin Hehenberger, M.D., Ph.D to Senior Vice President
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 May 2014
The BD MAX(TM) Enteric Bacterial Panel Receives FDA Clearance to Detect the Most Common Causes of Bacterial Gastroenteritis
Diagnostics FDA
 HSMN NewsFeed - 5 May 2014
Immune Pharmaceuticals Announces Phase 3 Development and Commercialization Strategy for AMIKET
Biopharmaceuticals
 HSMN NewsFeed - 28 Apr 2014
GW Pharmaceuticals Announces That Sativex Receives Fast Track Designation From FDA in Cancer Pain
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Apr 2014
Mallinckrodt Pharmaceuticals And Questcor Pharmaceuticals Enter Into Definitive Merger Agreement Under Which Mallinckrodt Will Acquire Questcor For Approximately $5.6 Billion, Creating A Diversified, High-Growth Specialty Pharmaceuticals Company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 2 Apr 2014
Immune CEO Announces New Operational Leadership Team
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Mar 2014
Synergy Pharmaceuticals Appoints Marino Garcia as Senior Vice President, Corporate Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 28 Feb 2014
GW Pharmaceuticals Receives Orphan Drug Designation by FDA for Epidiolex(R) in the Treatment of Lennox-Gastaut Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Jan 2014
Ipsen and GW Pharmaceuticals plc Enter into Agreement for Ipsen to Promote and Distribute Sativex(R) in Latin America
Biopharmaceuticals Neurology Distribution
 HSMN NewsFeed - 7 Jan 2014
Shield Therapeutics' ST10 Delivers Robust Results Meeting both Primary and Secondary Endpoints in the Pivotal AEGIS Phase 3 Programme for the Treatment of Iron Deficiency Anaemia in Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 20 Dec 2013
Coronado Biosciences Announces Management Changes
Biopharmaceuticals Personnel
 HSMN NewsFeed - 19 Dec 2013
Takeda Announces Exclusive License and Option Agreement with Natrogen for Development of Natura-alpha for Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 9 Dec 2013
FDA Advisory Committee Recommends Approval of Takeda's Investigational Biologic Vedolizumab
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 27 Nov 2013
GW Pharmaceuticals plc Announces Sativex(R) Regulatory Approval in Switzerland
Biopharmaceuticals Neurology Regulatory
 HSMN NewsFeed - 13 Nov 2013
Synergy Pharmaceuticals Initiates First Phase 3 Clinical Trial of Plecanatide in Patients with Chronic Idiopathic Constipation
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 7 Nov 2013
Salix Pharmaceuticals to Acquire Santarus
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 6 Nov 2013
Coronado Biosciences Announces Personnel Realignment, Including Appointment of Kevin Horgan, M.D., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Oct 2013
Cimzia(R) (Certolizumab Pegol) Approved by FDA for Treatment of Adults with Active Ankylosing Spondylitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 15 Oct 2013
Given Imaging Announces Data Confirming PillCam(R) SB Can Improve Management and Outcomes in Patients With Crohn's Disease
Devices Gastroenterology
 HSMN NewsFeed - 15 Oct 2013
Immune Pharmaceuticals Announces Changes to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 16 Sep 2013
FDA Grants Soligenix Orphan Drug Designation for SGX94 for Treatment of Acute Radiation Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Aug 2013
GW Pharmaceuticals Announces Results of MS Spasticity Study Confirming Sativex Has No Long-Term Negative Effect on Cognition
Biopharmaceuticals Neurology
 HSMN NewsFeed - 22 Jul 2013
GW Pharmaceuticals Files New Regulatory Application to Expand Sativex(R) Approval to France
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Jul 2013
Celgene Will Discontinue Phase III ORIGIN(R) Trial in Previously Untreated Elderly Patients with B-Cell Chronic Lymphocytic Leukemia
Biopharmaceuticals Oncology
 HSMN NewsFeed - 8 Jul 2013
GW Pharmaceuticals plc Announces Sativex(R) Launch in Italy
Biopharmaceuticals Neurology Product Launch
 HSMN NewsFeed - 11 Jun 2013
Questcor Pharmaceuticals Acquires Rights to Synacthen(R)
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 5 Jun 2013
Johnson & Johnson Innovation Announces Opening of the California Innovation Center
Devices
 HSMN NewsFeed - 7 May 2013
Coronado Biosciences Appoints Thomas F. Schaible, Ph.D. as Project Leader, Inflammatory Bowel Disease
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 24 Apr 2013
Coronado Biosciences Announces Departure of Dr. Bobby W. Sandage, Jr.
Biopharmaceuticals Personnel
 HSMN NewsFeed - 14 Feb 2013
Santarus Announces Commercial Launch of UCERIS (budesonide) Extended Release Tablets
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Feb 2013
Warner Chilcott Announces FDA Approval of New Ulcerative Colitis Product
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 18 Dec 2012
Avaxia Biologics Raises $6.4 Million in Series B Financing
Biopharmaceuticals Gastroenterology Venture Capital
 HSMN NewsFeed - 8 Nov 2012
Immune Pharmaceuticals and EpiCept Corporation Agree to Merge
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 22 Oct 2012
Abbott Announces Three-Year Long-Term Data Evaluating Efficacy with HUMIRA(R) (Adalimumab) For Patients with Moderately to Severely Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 31 Jul 2012
Prometheus Launches New Monitoring Test To Help Guide Inflammatory Bowel Disease Management
Diagnostics Personalized Medicine Gastroenterology
 HSMN NewsFeed - 22 May 2012
New Studies Confirm Given Imaging's PillCam(R) COLON 2's Feasibility in an Outpatient Setting
Devices Gastroenterology
 HSMN NewsFeed - 11 May 2012
Takeda Announces GEMINI II Trial of Vedolizumab in Patients with Moderately to Severely Active Crohn’s Disease Met Primary Endpoints of Improvement in Clinical Remission in Induction and Maintenance Phases
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 25 Apr 2012
Coronado Biosciences Promotes Karin Hehenberger, M.D., Ph.D., to Executive Vice President and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Apr 2012
Santarus Appoints Alessandro E. Della Chà and Matthew W. Strobeck to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Feb 2012
Santarus Announces FDA Acceptance of UCERIS New Drug Application for Induction of Remission of Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 13 Feb 2012
Santarus Announces Initiation of Phase IIIb Study with UCERIS in Patients with Mild or Moderate Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 6 Feb 2012
Santarus Begins Promoting Cholesterol-Lowering Product FENOGLIDE
Biopharmaceuticals
 HSMN NewsFeed - 20 Jan 2012
Remicade(R) (Infliximab) Receives Positive Opinion From CHMP In Europe for Treatment of Ulcerative Colitis in Pediatric Patients
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 20 Jan 2012
Ventrus Appoints New Board Member
Biopharmaceuticals Personnel
 HSMN NewsFeed - 31 Oct 2011
Given Imaging Announces New Studies Validate Use of PillCam SB(R) to Detect and Monitor Crohn's Disease
Devices Gastroenterology
 HSMN NewsFeed - 3 Oct 2011
Coronado Biosciences Appoints Noah D. Beerman as Executive Vice President and Chief Operating Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Sep 2011
Astellas and Theravance Announce European Marketing Authorization for VIBATIV(R) for Nosocomial Pneumonia Caused by MRSA
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 13 Sep 2011
IMMUNE Pharmaceuticals Announces Alan G. Harris MD, PhD, FRCP as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Sep 2011
Pfizer Announces Detailed Pivotal Data for Investigational Compound Tofacitinib in Rheumatoid Arthritis to be Presented at American College of Rheumatology 2011 Annual Scientific Meeting
Biopharmaceuticals
 HSMN NewsFeed - 6 Jul 2011
Coronado Biosciences Closes $25.8M in Series C Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 13 Jun 2011
Spectros Corporation Introduces Continuum(R), a Broadband Infrared Sensor for Brain and Gut Oximetry
Devices Monitoring
 HSMN NewsFeed - 10 May 2011
Abbott's HUMIRA(R) (Adalimumab) Meets Primary Endpoints in Phase III Ulcerative Colitis Study
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 28 Apr 2011
Pfizer Announces Top-Line Results Of Final Two Pivotal Phase 3 Trials Of Tofacitinib (CP-690,550) In Patients With Active Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 31 Mar 2011
VICTRELIS(TM) (boceprevir), Merck's Investigational Medicine, Added to Peginterferon Alfa-2a and Ribavirin Achieved Significantly Higher SVR Rates In Treatment-Failure Patients with Chronic HCV Genotype 1 Compared to Control
Biopharmaceuticals
 HSMN NewsFeed - 10 Mar 2011
Given Imaging Receives FDA Clearance for Expanded PillCam(R) SB Indications
Devices Gastroenterology FDA
 HSMN NewsFeed - 28 Feb 2011
Santarus and Pharming Announce Receipt of FDA Refusal to File Letter for RHUCIN Biologics License Application
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Feb 2011
Santarus and Pharming Announce Initiation of Phase IIIb Clinical Study with RHUCIN in Acute Hereditary Angioedema
Biopharmaceuticals
 HSMN NewsFeed - 8 Feb 2011
Given Imaging's PillCam(R) COLON Now Reimbursable for Hospital Inpatient Use in Germany
Devices Gastroenterology Reimbursement
 HSMN NewsFeed - 28 Dec 2010
Pharming and Santarus announce submission of Rhucin Biologics License Application to FDA
Biopharmaceuticals
 HSMN NewsFeed - 15 Nov 2010
Santarus Announces Commercial Launch of Novel Type 2 Diabetes Drug CYCLOSET
Biopharmaceuticals Endocrinology
 HSMN NewsFeed - 8 Nov 2010
New Anti-TNF Study Shows Patients With Rheumatoid Arthritis Receiving REMICADE(R) After Inadequate Response to Enbrel(R) or Humira(R) Demonstrate Marked Clinical Improvement
Biopharmaceuticals
 HSMN NewsFeed - 29 Oct 2010
Forest Announces FDA Approval of Teflaro(TM) (ceftaroline fosamil) for the Treatment of Community-Acquired Bacterial Pneumonia and Acute Bacterial Skin and Skin Structure Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Oct 2010
RHUCIN Clinical Trial Data Published in the Journal of Allergy and Clinical Immunology
Biopharmaceuticals
 HSMN NewsFeed - 13 Sep 2010
Pharming signs commercialization agreement with Santarus for Rhucin(R) in North America
Biopharmaceuticals
 HSMN NewsFeed - 30 Aug 2010
Meda acquires Alaven, a US specialty pharma company
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 8 Jun 2010
Salix Pharmaceuticals Announces NDA Submission For XIFAXAN550 For Treatment of Non-Constipation Irritable Bowel Syndrome
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 5 May 2010
New Studies Presented at Digestive Disease Week Highlight the Value of PillCam(R) Capsule Endoscopy
Devices Gastroenterology
 HSMN NewsFeed - 15 Apr 2010
REMICADE(R) Study Results Show Greater Steroid-Free Remission and Mucosal Healing Compared With Conventional Immunomodulator Azathioprine in Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 25 Mar 2010
Santarus Announces Completion of Enrollment in U.S. Phase III Clinical Study for Budesonide MMX
Biopharmaceuticals Drug Delivery Gastroenterology
 HSMN NewsFeed - 24 Mar 2010
FDA Approves XIFAXAN(R) 550 MG Tablets for Reduction in Risk of Overt Hepatic Encephalopathy (HE) Recurrence
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Mar 2010
PhytoMedical Announces the Appointment of Dr. James F. Lynch as President and CEO
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 1 Feb 2010
Human Genome Sciences Names Scott Habig Vice President, Sales
Biopharmaceuticals Personnel
 HSMN NewsFeed - 11 Jan 2010
ViroPharma Expands Global Licensing, Commercialization and Development Rights for Cinryze(TM) (C1 esterase inhibitor [human])
Biopharmaceuticals Licensing
 HSMN NewsFeed - 16 Dec 2009
Nanotherapeutics Acquires Two Late Stage Clinical Programs for Alzheimer's Treatment and CDA Disease
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 27 Nov 2009
Theravance Receives Complete Response Letter on the Telavancin NDA for the Treatment of Nosocomial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Nov 2009
Theravance and Astellas Announce the Commercial Launch of VIBATIV(TM) (telavancin) in the United States
Biopharmaceuticals
 HSMN NewsFeed - 28 Oct 2009
Shire Secures European Wide Label Extension for FOSRENOL(R) in Chronic Kidney Disease
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Oct 2009
New Data Presented From WELCOME Trial Show Positive Impact of CIMZIA(R) (certolizumab pegol) on Hospitalizations and Surgeries in Patients With Prior Infliximab Failure
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Oct 2009
New SIMPONI(TM) Data Show Inhibition of Joint Damage in Patients With Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 7 Oct 2009
Data From a Head-to-Head Crossover Study Evaluating FOSRENOL(R) and Sevelamer Published Today
Biopharmaceuticals
 HSMN NewsFeed - 5 Oct 2009
FDA Advisory Committee Recommends Approval of PEGINTRON(R) for the Adjuvant Treatment of Stage III Malignant Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 1 Oct 2009
Astellas and Theravance Announce Approval of VIBATIV(TM) (telavancin) in Canada for the Treatment of Complicated Skin and Skin Structure Infections
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 23 Sep 2009
Pluristem Therapeutics Doses First Patient in U.S. With Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
Regenerative Medicine
 HSMN NewsFeed - 10 Sep 2009
Ritter Pharmaceuticals Hires Dr. Howard Foyt as Executive Vice President, Development & Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 10 Sep 2009
Pluristem Begins Enrollment in U.S. With Unmatched Placenta-Derived Stem Cell Product PLX-PAD in a Phase I Clinical Trial for Treatment of Peripheral Artery Disease
Regenerative Medicine
 HSMN NewsFeed - 24 Aug 2009
Warner Chilcott Acquires P&G's Global Pharmaceuticals Business
Biopharmaceuticals Acquisitions
 HSMN NewsFeed - 13 Jul 2009
Cepheid Receives FDA Clearance for First On-Demand Molecular Diagnostic Test for Clostridium difficile Infection
Diagnostics FDA
 HSMN NewsFeed - 16 Jun 2009
Pluristem Therapeutics Receives European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
Regenerative Medicine
 HSMN NewsFeed - 15 Jun 2009
Hollis-Eden Pharmaceuticals Announces Appointment of Dr. James M. Frincke President and CEO
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jun 2009
ViroPharma Announces Appointment of Frank Baldino, Jr., Ph.D. to Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Jun 2009
Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 15 May 2009
AGI Therapeutics: Top-line results of Phase III study of Rezular
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 30 Mar 2009
Inverness Medical Innovations Launches New FDA Cleared C. DIFF QUIK CHEK COMPLETE(TM) Rapid Test
Diagnostics
 HSMN NewsFeed - 24 Mar 2009
FDA Approves New Indication for Wyeth's TYGACIL (tigecycline) for the Treatment of Adult Patients with Community-Acquired Bacterial Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Mar 2009
FDA Approves an Expanded Indication for Peginterferon-Based Combination Therapy for Patients With Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 11 Mar 2009
Shire Announces Launch of FOSRENOL(R) in Japan
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 10 Mar 2009
FDA Grants Orphan Drug Designation for EUR-1073
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 13 Feb 2009
ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 9 Feb 2009
Sagent Pharmaceuticals Announces Expansion of Cefazolin Product Line to Include Cefazolin for Injection, USP in 500mg Single-Dose Vial
Biopharmaceuticals
 HSMN NewsFeed - 9 Feb 2009
ViroPharma Reports Results of Phase 3 Clinical Trial for Maribavir in Bone Marrow Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 3 Feb 2009
FDA Grants Priority Review of a Supplemental Biologics License Application for Cinryze(TM) C1 Inhibitor (Human) as Treatment for Acute Attacks of Hereditary Angioedema (HAE)
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Feb 2009
Hollis-Eden Pharmaceuticals Announces Cost-Cutting Measures to Focus Resources on Advancement of Ongoing Clinical Development Programs
Biopharmaceuticals
 HSMN NewsFeed - 27 Jan 2009
Schering-Plough Completes Enrollment of Boceprevir Registration Studies in Treatment-Naive and Treatment-Experienced HCV Patients
Biopharmaceuticals
 HSMN NewsFeed - 12 Jan 2009
The Medicines Company to Acquire Targanta Therapeutics
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 29 Dec 2008
Salix Receives FDA Complete Response Letter for Balsalazide Tablet
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 15 Dec 2008
COSMO ANNOUNCES STRATEGIC COLLABORATION WITH SANTARUS FOR U.S. RIGHTS TO BUDESONIDE MMX® AND RIFAMYCIN SV MMX®
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 10 Dec 2008
MorphoSys Appoints Dr. Arndt Schottelius as Chief Development Officer and Member of the Management Board
Biopharmaceuticals Personnel
 HSMN NewsFeed - 24 Nov 2008
Schering-Plough Provides Update on Boceprevir Clinical Development and Introduces Potent Next-Generation Oral HCV Protease Inhibitor for Treating Patients With Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 10 Nov 2008
Cepheid Launches First On-Demand Molecular Diagnostic Test for Clostridium Difficile Into European Market
Diagnostics
 HSMN NewsFeed - 3 Nov 2008
APRISO(TM) Granted FDA Marketing Approval for Maintenance of Remission of Ulcerative Colitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Oct 2008
ConvaTec Launches SUR-FIT Natura(R) Low-Pressure Adaptor
Devices Wound Care
 HSMN NewsFeed - 27 Oct 2008
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
Biopharmaceuticals
 HSMN NewsFeed - 21 Oct 2008
ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 21 Oct 2008
Abbott's HUMIRA(R) (adalimumab) Data Shows Fistula Healing for Up to Three Years in Patients with Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 21 Oct 2008
New Multicenter Study Underscores Value of Using PillCam(R) SB in Children Younger Than 8
Devices Gastroenterology
 HSMN NewsFeed - 20 Oct 2008
PillCam(R) COLON Shows Substantial Agreement With Gold Standard Colonoscopy in Detection of Ulcerative Colitis
Devices Gastroenterology
 HSMN NewsFeed - 8 Oct 2008
One Year of GATTEX(TM) Therapy Safely Reduces Parenteral Nutrition Dependence for Patients with Short Bowel Syndrome
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 6 Oct 2008
CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 18 Sep 2008
Findings From Landmark Study Show Ustekinumab Demonstrated Superior Efficacy to Enbrel(R) (Etanercept) in Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 18 Sep 2008
Continuous Treatment With Abbott's HUMIRA(R) Achieves Superior Long-Term Efficacy for Psoriasis Patients Compared to Interrupting Treatment
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 8 Aug 2008
FDA Extends Review Timeline for Ustekinumab Biologic License Application Three Months
Biopharmaceuticals FDA
 HSMN NewsFeed - 4 Aug 2008
Pluristem Appoints Ms. Chaya Mazouz Clinical Operations Director
Regenerative Medicine Personnel
 HSMN NewsFeed - 15 Jul 2008
ViroPharma To Acquire Lev Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 14 Jul 2008
Given Imaging Announces PillCam(R) Capsule Endoscopy of the Small Bowel Recognized as Primary Evaluation Tool by Largest Payer in Ohio
Devices Gastroenterology
 HSMN NewsFeed - 11 Jul 2008
Long-Term Pegylated Interferon Alfa-2b Therapy in Stage III Melanoma Demonstrated Significant and Sustained Impact on Relapse-Free Survival
Biopharmaceuticals Oncology
 HSMN NewsFeed - 9 Jul 2008
Study Shows That PillCam(R) SB Helps Doctors Treat Children With Crohn's Disease More Effectively
Devices Gastroenterology
 HSMN NewsFeed - 2 Jul 2008
Cubist Pharmaceuticals to Promote in the U.S. AstraZeneca's Broad Spectrum Antibiotic, MERREM I.V.
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2008
Centocor, Inc. Submits Application to FDA Requesting Approval of Golimumab for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals
 HSMN NewsFeed - 17 Jun 2008
FDA Advisory Committee Unanimously Recommends Approval of Ustekinumab for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 13 Jun 2008
Data Show that Abbott's HUMIRA(R) (adalimumab) Reduced the Signs and Symptoms of Ankylosing Spondylitis Up to Three Years
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2008
HUMIRA(R) (adalimumab) Data Show That Treating Early Rheumatoid Arthritis With Combination Treatment Resulted in Cost Savings From Improved Work Productivity
Biopharmaceuticals
 HSMN NewsFeed - 13 Jun 2008
New Long-Term HUMIRA(R) (adalimumab) Data Show Up to Seven-Year Efficacy with Combination Treatment for Rheumatoid Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2008
Phase 3 Data Show Efficacy of Golimumab in Patients with Active Rheumatoid Arthritis Previously Treated with Anti-TNF Agents
Biopharmaceuticals
 HSMN NewsFeed - 11 Jun 2008
Data From Two Phase 3 Studies Show Anti-TNF Golimumab Significantly Improved Signs and Symptoms of Rheumatoid Arthritis
Biopharmaceuticals Oncology
 HSMN NewsFeed - 29 May 2008
Wyeth Receives Approvable Letter from FDA for TYGACIL for the Treatment of Patients with Community-Acquired Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 21 May 2008
Schering-Plough To Initiate Phase III Studies With HCV Protease Inhibitor Boceprevir in Previously Untreated Hepatitis C Patients and Those Who Failed Prior Treatment
Biopharmaceuticals
 HSMN NewsFeed - 20 May 2008
Newly-Approved Cimzia(R) Provides Rapid, Sustained Response in Crohn's Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 May 2008
Phase 3 GATTEX(TM) Results Presented at Annual Digestive Disease Week Congress Highlight Potential New Treatment in Short Bowel Syndrome
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Apr 2008
FDA Approval of Cimzia(R) for Crohn's Disease Represents Latest Milestone for Nektar's PEGylation Technology Platform
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 22 Apr 2008
Cimzia(R) Approved in the US for the Treatment of Moderate to Severe Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 17 Apr 2008
Schering-Plough Highlights PEGINTRON(TM) and Boceprevir Data Presentations at European Association for the Study of the Liver (EASL) Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 16 Apr 2008
Abbott Announces HUMIRA(R) (adalimumab) Approved in Japan for the Treatment of Rheumatoid Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 27 Mar 2008
Pegintron(TM) Plus Weight-Based Rebetol(R) Resulted in Higher SVR Than Flat Dosing; Low Relapse Rates in Patients With Chronic Hepatitis C
Biopharmaceuticals FDA
 HSMN NewsFeed - 26 Mar 2008
Shire and TAP Agree to Co-promote LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 18 Mar 2008
Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Mar 2008
NPS Reports Successful GATTEX(TM) Extension Study
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 Mar 2008
Hollis-Eden Pharmaceuticals Provides Update on Clinical Development Program; Announces Fourth Quarter and Year-End 2007 Financial Results
Biopharmaceuticals
 HSMN NewsFeed - 13 Mar 2008
Salix Acquires Budesonide Products from Dr. Falk Pharma
Biopharmaceuticals Licensing
 HSMN NewsFeed - 13 Mar 2008
Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
Biopharmaceuticals Generics
 HSMN NewsFeed - 4 Mar 2008
UCB: Early Data on Cimzia(R) from the WELCOME Study Show Efficacy in Infliximab-Refractory Crohn's Disease Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 3 Mar 2008
Given Imaging Announces New Mayo Clinic Study Concludes Celiac Disease May Be More Severe Than Symptoms Indicate for Some Patients
Devices Gastroenterology
 HSMN NewsFeed - 12 Feb 2008
Altor BioScience In-Licenses Tissue Factor Antagonists from Genentech
Biopharmaceuticals Licensing
 HSMN NewsFeed - 4 Feb 2008
Centocor Announces Ustekinumab Biologic License Application Accepted for Filing by FDA
Biopharmaceuticals Dermatology FDA
 HSMN NewsFeed - 31 Jan 2008
FDA Grants Priority Review for Schering-Plough's Peginterferon Alfa-2b for the Adjuvant Treatment of Patients With Stage III Melanoma
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 24 Jan 2008
FDA Approves MiddleBrook's Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 18 Jan 2008
Abbott's HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
Biopharmaceuticals FDA
 HSMN NewsFeed - 17 Jan 2008
Shire Completes Fosrenol(R) Roll-Out in Major European Markets With Launch in Spain
Biopharmaceuticals
 HSMN NewsFeed - 14 Jan 2008
Roche responds to announcement of 'IDEAL' hepatitis C trial results
Biopharmaceuticals
 HSMN NewsFeed - 8 Jan 2008
Callisto Pharmaceuticals Announces Investor Conference Call to Provide Details on Guanilib Strategic Initiative in GI Disorders
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 8 Jan 2008
ViroPharma Provides Update on Vancocin(R)
Biopharmaceuticals
 HSMN NewsFeed - 4 Jan 2008
Cerimon Pharmaceuticals Names Matthew J. Meyer its General Counsel and Vice President of Business Development and Licensing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2008
ViroPharma Augments Senior Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 3 Jan 2008
DOR BioPharma Receives Orphan Drug Designation for Oral BDP for the Treatment of Pediatric Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 31 Dec 2007
Salix Pharmaceuticals Announces Submission of Granulated Mesalamine New Drug Application
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 21 Dec 2007
Centocor, Schering-Plough Revise Agreement Covering REMICADE, Golimumab
Biopharmaceuticals Distribution
 HSMN NewsFeed - 20 Dec 2007
Abbott's HUMIRA(R) Approved in the European Union for Treatment of Moderate-to-Severe Plaque Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Dec 2007
Hollis-Eden Pharmaceuticals Announces Cystic Fibrosis Foundation Therapeutics Selects TRIOLEX(TM) (HE3286) as a Next-Generation Oral Anti-Inflammatory Drug Candidate
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2007
Study Data Show Asacol(R) (Mesalamine) is Effective in Treating All Extents of Ulcerative Colitis Including Isolated Proctitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 4 Dec 2007
Centocor and Janssen-Cilag Submit Applications Requesting Approval of Ustekinumab in the U.S. and Europe for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals FDA Regulatory
 HSMN NewsFeed - 27 Nov 2007
Cook Medical Delivers Innovative Treatment for Recto-Vaginal Fistulas
Devices
 HSMN NewsFeed - 16 Nov 2007
Abbott's HUMIRA(R) Receives Positive Opinion From EMEA for Treatment of Moderate to Severe Plaque Psoriasis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 15 Nov 2007
PEGINTRON(TM) and REBETOL(R) Approved in European Union for Retreating Hepatitis C Patients Who Failed Previous Pegylated or Non-Pegylated Interferon Therapy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Nov 2007
ViroPharma Receives European Orphan Drug Designation for CAMVIA(TM)
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Nov 2007
Phase 3 Data Show New Anti-TNF, Golimumab, Significantly Improved Arthritis, Skin and Nail Manifestations in Patients with Psoriatic Arthritis
Biopharmaceuticals
 HSMN NewsFeed - 8 Nov 2007
New Anti-TNF Golimumab Significantly Reduced Signs and Symptoms Of Ankylosing Spondylitis According to Phase 3 Study Findings
Biopharmaceuticals
 HSMN NewsFeed - 7 Nov 2007
Prometheus to Acquire Lotronex(R) From GlaxoSmithKline
Biopharmaceuticals Gastroenterology Acquisitions
 HSMN NewsFeed - 6 Nov 2007
REMICADE(R) Becomes First Anti-TNF Biologic Therapy to Treat One Million Patients Worldwide
Biopharmaceuticals
 HSMN NewsFeed - 6 Nov 2007
Shire Announces Results of FOSRENOL(R) Study in Pre-Dialysis CKD Stage 3 & 4 Patients
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2007
Treatment with PEGASYS(R)/COPEGUS(TM) Provides Hope for Hepatitis C Patients Whose Infection Did Not Initially Respond to Peg-Intron(R)/Ribavirin
Biopharmaceuticals
 HSMN NewsFeed - 2 Nov 2007
Roche's Investigational Polymerase Inhibitor, Combined with PEGASYS(R) and COPEGUS(TM), Shows Potent Antiviral Activity in Treatment of Chronic Hepatitis C at Four Weeks
Biopharmacetuicals
 HSMN NewsFeed - 30 Oct 2007
Significant New Data on Roche's PEGASYS(R) and Hepatitis C Pipeline Compounds to be Featured at 58th Annual AASLD Meeting
Biopharmaceuticals
 HSMN NewsFeed - 24 Oct 2007
FDA Accepts Wyeth's Supplemental New Drug Application for Tygacil for the Treatment of Patients with Community-Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 19 Oct 2007
DOR BioPharma Receives Not Approvable Letter From FDA for orBec(R) for Treatment of Gastrointestinal Graft-versus-Host Disease
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Oct 2007
FDA Advisory Committee Votes in Favor of Earlier Use of Phosphate Binders in Stage 4 Kidney Disease Patients With Hyperphosphatemia
Biopharmaceuticals
 HSMN NewsFeed - 15 Oct 2007
Clinical Studies Show REMICADE Reduces Incidence of Bowel Surgeries in Ulcerative Colitis Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 15 Oct 2007
FDA Approves DORIBAX(TM) for the Treatment of Complicated Intra-Abdominal and Complicated Urinary Tract Infections
Biopharmaceuticals Urology FDA
 HSMN NewsFeed - 15 Oct 2007
New Analysis of Study Data Shows That Asacol(R) (Mesalamine) Delivers Rapid Symptom Relief for Ulcerative Colitis Patients
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 8 Oct 2007
Shire Divests Non-Core Product Portfolio to Almirall
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 4 Oct 2007
Salix Announces Statistically Significant Top- Line Results for Second Product Registration Study of Granulated Mesalamine in Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 4 Oct 2007
Salix Pharmaceuticals Licenses OSMOPREP(TM) To Mayoly-Spindler in France
Biopharmaceuticals Licensing Gastroenterology
 HSMN NewsFeed - 3 Oct 2007
Promising Phase 3 Trial Results Show Novel Biologic Therapy Ustekinumab (CNTO 1275) Significantly Improved Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 27 Sep 2007
Asphelia Pharmaceuticals Appoints Francois-Xavier Frapaise As President and Chief Executive Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 26 Sep 2007
NPS Pharmaceuticals and Nycomed Announce Licensing Agreement for GATTEX(TM) in Territories Outside North America
Biopharmaceuticals Gastroenterology Licensing
 HSMN NewsFeed - 24 Sep 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Sep 2007
Altheus Therapeutics Secures $3.6 Million in Venture Capital
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Sep 2007
Eisai Inc. Enters Copromotion Agreement with Salix Pharmaceuticals, Ltd. for Balsalazide Products
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Sep 2007
Salix Pharmaceuticals Announces Co-Promotion Agreement for Balsalazide
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 28 Aug 2007
PDL BioPharma Announces Significant Strategic and Portfolio Changes to Focus on Antibody Discovery and Development
Biopharmaceuticals
 HSMN NewsFeed - 18 Jul 2007
Pivotal CIMZIA(TM) Data in Crohn's Disease Published in New England Journal of Medicine
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 Jul 2007
Aventir Biotech Launches New 510(k) Cleared Fecal Occult Blood Screen Test
Diagnostics FDA
 HSMN NewsFeed - 10 Jul 2007
ViroPharma Announces Key Additions to European Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Jul 2007
Genzyme Announces Data from First Phase 3 Study of Tolevamer in Patients with C. difficile Associated Diarrhea
Biopharmaceuticals
 HSMN NewsFeed - 5 Jul 2007
ViroPharma Initiates Phase 3 Study of CAMVIA(TM) (maribavir) in Liver Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 27 Jun 2007
FDA Grants Fast Track Status for HCV-796 for Treatment of Hepatitis C Virus Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 Jun 2007
PEGINTRON(TM) and REBETOL(R) Combination Therapy Approved in European Union for Treating Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 18 Jun 2007
Salix Pharmaceuticals Announces Positive Top Line Results of Balsalazide Tablets Registration Study
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 15 Jun 2007
REMICADE(R) Two Year Data in Ankylosing Spondylitis Show Improvement in Spinal Mobility and Spinal Inflammation
Biopharmaceuticals
 HSMN NewsFeed - 14 Jun 2007
Axcan Pharma Initiates MAX-002 Phase III Clinical Trial to Evaluate the Efficacy and Safety of a High-Concentration 1 Gram Mesalamine Suppository
Biopharmaceuticals
 HSMN NewsFeed - 12 Jun 2007
July Issue of Journal of Antimicrobial Chemotherapy Highlights Study of FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Biopharmaceuticals
 HSMN NewsFeed - 8 Jun 2007
Callisto Pharmaceuticals Files Suit Against Former Executive Vice President for Breach of Employment Agreement, Fraud, Conversion and Related Claims
Biopharmaceuticals Personnel
 HSMN NewsFeed - 8 Jun 2007
Salix Pharmaceuticals Announces Imminent Launch of Visiclear(R) in Japan
Biopharmaceuticals
 HSMN NewsFeed - 7 Jun 2007
Abbott's HUMIRA(R) (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 7 Jun 2007
Remicade(R) Receives EU Approval as First and Only Biologic Treatment for Pediatric Crohn's Disease
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 3 Jun 2007
Patients Who Took Investigational Melanoma Compound CP-675,206 Showed Favorable Survival Outcomes, Pfizer Says
Biopharmaceuticals Oncology
 HSMN NewsFeed - 23 May 2007
Prolacta Bioscience Closes on over $12 Million in Private Funding
Biopharmaceuticals Venture Capital Personnel
 HSMN NewsFeed - 22 May 2007
New Analysis of Data Shows Treatment With Abbott's HUMIRA(R) (Adalimumab) Significantly Reduced Disease-Related Hospitalization for Patients with Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 May 2007
Analysis of Ulcerative Colitis (UC) Remission Rates from Long-term Safety Study of LIALDA(TM) (mesalamine) Presented at DDW
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 May 2007
UCB Presents Long-Term CIMZIA(TM) Data in Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 17 May 2007
Ulcerative Colitis (UC) Sufferers Find UC Quite Disruptive to Many Aspects of Daily Life
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 10 May 2007
Abraxis BioScience Receives FDA Approvals for Clindamycin Injection, USP
Biopharmaceuticals Generics FDA
 HSMN NewsFeed - 9 May 2007
FDA Advisory Panel Reviews DOR BioPharma's orBec(R) for Treatment of GI GVHD
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 May 2007
FDA Approves Oscient Pharmaceuticals' FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 1 May 2007
Robert G. Pietrusko Joins ViroPharma as Vice President of Global Regulatory Affairs and Quality
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 May 2007
ViroPharma Announces Decision To Develop And Commercialize Maribavir In Europe
Biopharmaceuticals
 HSMN NewsFeed - 30 Apr 2007
European Union's CHMP Issues Positive Opinion on PEGINTRON(Tm) and REBETOL(R) Combination Therapy for Hepatitis C in Patients Coinfected With HIV
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 26 Apr 2007
PDL BioPharma Advances Nuvion(R) Into Second Pivotal Study in Intravenous Steroid-Refractory Ulcerative Colitis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 11 Apr 2007
Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 10 Apr 2007
Abbott Opens New Biotechnology Manufacturing Facility in Puerto Rico
Biopharmaceuticals
 HSMN NewsFeed - 9 Apr 2007
OXIS International Expands Licensing Deal with Alteon to Include Exclusive Rights of Organoselenium Compounds for All Indications
Biopharmaceuticals Licensing
 HSMN NewsFeed - 5 Apr 2007
PEGINTRON(TM) Approved in China for Treating Chronic Hepatitis B
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Apr 2007
Protemix Raises US$14.5 Million in First Close of Series A Financing
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 26 Mar 2007
European Union CHMP Recommends Approval of First and Only Biologic Treatment for Pediatric Crohn's Disease: REMICADE(R)
Biopharmaceuticals Regulatory Gastroenterology
 HSMN NewsFeed - 23 Mar 2007
UCB Provides Update on CIMZIA(TM) for Crohn's Disease and Rheumatoid Arthritis in the US
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Mar 2007
LIALDA(TM) (mesalamine) With MMX(TM) Technology - the First Oral Once-Daily Mesalamine for Active, Mild to Moderate Ulcerative Colitis - Now Available
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Mar 2007
UK Launch Expands Global Reach of FOSRENOL(R)
Biopharmaceuticals
 HSMN NewsFeed - 2 Mar 2007
Abbott Canada Launches Oscient Pharmaceuticals' FACTIVE Tablets in Canada
Biopharmacetuicals
 HSMN NewsFeed - 27 Feb 2007
HUMIRA(R) (Adalimumab) Receives FDA Approval For Treatment of Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 22 Feb 2007
New Treatment Guidelines for Community-Acquired Pneumonia Highlight Utility of FACTIVE Tablets
Biopharmaceuticals
 HSMN NewsFeed - 12 Feb 2007
sanofi-aventis Announces Update to U.S. Prescribing Information for Ketek(R) (Telithromycin)
Biopharmaceuticals FDA
 HSMN NewsFeed - 7 Feb 2007
ViroPharma Receives Orphan Drug Designation for Maribavir for Cytomegalovirus Viremia and Disease Indication
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 Feb 2007
New Analyses Reinforce Efficacy of REMICADE(R) in Treatment of Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 2 Feb 2007
REMICADE(R) Therapy Shown to Improve Productivity in Patients Treated for Chronic Plaque Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 31 Jan 2007
Procter & Gamble Pharmaceuticals Commemorates 15 Years of Trusted Leadership With Asacol(R) (Mesalamine) Delayed-Release Tablets
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 26 Jan 2007
Oscient Pharmaceuticals Completes Enrollment in Phase IV Trial of FACTIVE Tablets
Biopharmaceuticals
 HSMN NewsFeed - 23 Jan 2007
Cook Surgery Reports Significant Hospital Medicare Reimbursement for Promising New Fistula Repair Procedure
Devices Reimbursement
 HSMN NewsFeed - 16 Jan 2007
FDA Approves LIALDA(TM) (mesalamine), the First Oral Once-Daily Mesalamine for Patients With Active, Mild to Moderate Ulcerative Colitis
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 12 Jan 2007
Pipex Pharmaceuticals Acquires Minority Interest in Its Effective Pharmaceuticals Subsidiary
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 11 Jan 2007
ELAPRASE(R) for the Treatment of Hunter Syndrome Approved by the European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 11 Jan 2007
The European Commission Approves First and Only Enzyme Replacement Therapy for Hunter Syndrome
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Jan 2007
Cerimon Pharmaceuticals Names Daniel Levitt, M.D., Ph.D. Executive Vice President of Research and Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 29 Dec 2006
Bradley Pharmaceuticals Announces Launch of Authorized Generic of Pamine(R) (methscopolamine bromide)
Biopharmaceuticals Generics
 HSMN NewsFeed - 28 Dec 2006
Dr. Geoffrey Henson to Join Callisto Pharmaceuticals
Biopharmaceuticals Oncology Personnel
 HSMN NewsFeed - 21 Dec 2006
New River Pharmaceuticals and Shire Receive Approvable Letter for VYVANSE(TM) (lisdexamfetamine dimesylate) for the Treatment of ADHD
Biopharmaceuticals
 HSMN NewsFeed - 21 Dec 2006
Callisto Pharmaceuticals Files Suit Against Tapestry Pharmaceuticals for Breach of Confidential Disclosure Agreement
Biopharmaceuticals Litigation
 HSMN NewsFeed - 20 Dec 2006
FDA Approves New Indication for INVANZ(R) (ertapenem) for the Prevention of Surgical Site Infections (SSI) following Elective Colorectal Surgery in Adults
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Dec 2006
Colazal(R) Pediatric Indication Approved
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 19 Dec 2006
Trillium's TTI-1612 product receives orphan drug designation in Europe and the United States
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 15 Dec 2006
Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the Approval of TYSABRI(R) as a Treatment for Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 13 Dec 2006
OSMOPREP(TM) Tablets Granted MHRA Marketing Approval
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 12 Dec 2006
Dr. Jeffrey Leiden Appointed Non Executive Director at Shire
Biopharmaceuticals Personnel
 HSMN NewsFeed - 12 Dec 2006
Valeant Pharmaceuticals Initiates Infergen(R) Phase 4 Study
Biopharmaceuticals
 HSMN NewsFeed - 5 Dec 2006
Cerimon Pharmaceuticals Names Ayse Kocak Vice President of Marketing
Biopharmaceuticals Personnel
 HSMN NewsFeed - 1 Dec 2006
Treatment of Ulcerative Colitis With Asacol Improved Patient Quality of Life in as Early as Three Weeks, According to New Data Analysis
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 27 Nov 2006
FDA Accepts as "Complete Response" Oscient Pharmaceuticals' Submission Following FACTIVE Approvable Letter for Five-Day CAP
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Nov 2006
New Analyses Demonstrate Positive Effect on Bone With Fosrenol(R) Treatment Compared With Standard Therapy
Biopharmaceuticals
 HSMN NewsFeed - 17 Nov 2006
FOSRENOL(R) Data Show Evidence of Trends Towards Improved Bone Formation in CKD Stage 5 Patients, New Data Presented at ASN Meeting
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Study Results With Once-Daily Guanfacine Extended Release (GXR) in ADHD Patients Aged 6-17
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of its Bioequivalence Study of SPD465, an Investigational Drug for Adults with ADHD
Biopharmaceuticals
 HSMN NewsFeed - 16 Nov 2006
Shire Announces Results of a Meta-Analysis Comparing Stimulant Medications to Non-Stimulant Medications in Treating ADHD in Patients Aged 8 to 15
Biopharmaceuticals
 HSMN NewsFeed - 10 Nov 2006
Shire Sues Andrx Pharmaceuticals, L.L.C.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 8 Nov 2006
Napo Pharmaceuticals, Inc. ("Napo" or "the Company") Appointment of VP Clinical Affairs and Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 7 Nov 2006
Callisto Pharmaceuticals Initiates Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer
Biopharmaceuticals Oncology
 HSMN NewsFeed - 7 Nov 2006
Daniel B. Soland Joins ViroPharma as Vice President and Chief Commercial Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 6 Nov 2006
Pipex Therapeutics Merges With Sheffield Pharmaceuticals
Biopharmaceuticals Mergers & Acquisitions
 HSMN NewsFeed - 30 Oct 2006
Valeant Pharmaceuticals Presents End-of-Treatment Results of DIRECT Trial for Infergen at the American Association for the Study of Liver Diseases 2006 Annual Meeting
Biopharmaceuticals
 HSMN NewsFeed - 27 Oct 2006
Results of PEG-INTRON(R) and REBETOL(R) Study in Retreating Hepatitis C Patients Who Failed Previous Combination Therapy Presented at AASLD
Biopharmaceuticals
 HSMN NewsFeed - 26 Oct 2006
DAYTRANA(TM) (methylphenidate transdermal system) Provides Individualized Symptom Management
Biopharmaceuticals
 HSMN NewsFeed - 23 Oct 2006
Given Imaging Announces Data Presented at American College of Gastroenterology Annual Meeting
Devices Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Data for Zelnorm(R) Demonstrate Relief of Multiple Symptoms of Dysmotility-Type Dyspepsia
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
Salix Pharmaceuticals Reports American College of Gastroenterology Update
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Data Show CIMZIA(TM) (certolizumab pegol) May Improve Productivity in Work and with Daily Activities for People with Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Analysis Shows CIMZIA(TM) (Certolizumab Pegol) Maintained Remission and Response in Recent Onset Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
New Efficacy Data Show CIMZIA(TM) (Certolizumab Pegol) Maintained Response and Remission in Crohn's Patients Previously Treated With Infliximab
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 Oct 2006
Data Show Treatment With Remicade(R) Reduced Hospitalizations for Ulcerative Colitis Patients By Half
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 19 Oct 2006
ELAPRASE(TM) (idursulfase) Receives Positive Opinion in Europe
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 19 Oct 2006
FDA Expands REMICADE(R) Indication for Ulcerative Colitis: Biologic Maintains Long-Term Clinical Remission and Mucosal Healing
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 13 Oct 2006
Data on FACTIVE(R) Tablets Short-Course Therapy in Patients with Co-Morbidities Presented at Annual Meeting of Infectious Diseases Society of America
Biopharmaceuticals
 HSMN NewsFeed - 11 Oct 2006
Stonebridge Pharma and Capellon Pharmaceuticals Announce Co-Promotion Agreement to Market Symax(TM) Duotab (hyoscyamine sulfate) for Irritable Bowel Syndrome
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 28 Sep 2006
United States Seeing Greater Increases in Clostridium Difficile-Associated Disease Case-Load and Severity
Biopharmaceuticals
 HSMN NewsFeed - 28 Sep 2006
ViroPharma Initiates First of Two Phase 3 Studies of Maribavir in Transplant Patients
Biopharmaceuticals
 HSMN NewsFeed - 28 Sep 2006
Cerimon Pharmaceuticals Names Timothy J. McBride as Senior Vice President of Business Development
Biopharmaceuticals Personnel
 HSMN NewsFeed - 27 Sep 2006
FDA Approves REMICADE(R) for Treatment of Chronic Severe Plaque Psoriasis: Marks Major Milestone for Patients With High Disease Burden
Biopharmaceuticals FDA
 HSMN NewsFeed - 27 Sep 2006
Colazal(R) Food Effect Application Granted FDA Approval
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 26 Sep 2006
Callisto Pharmaceuticals Granted Orphan Drug Designation for Atiprimod to Treat Carcinoid Tumors
Biopharmaceuticals Oncology FDA
 HSMN NewsFeed - 22 Sep 2006
Oscient Pharmaceuticals Receives Approvable Letter from FDA for FACTIVE(R) Tablets for Five-Day Treatment of Community-Acquired Pneumonia
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Sep 2006
BioBalance Announces the Resignation of Its CEO and the Assumption of Additional Duties by Richard Serbin
Biopharmaceuticals Gastroenterology Personnel
 HSMN NewsFeed - 13 Sep 2006
Oscient Pharmaceuticals Announces Results of FDA Advisory Committee Meeting for FACTIVE Tablets for the Treatment of Acute Bacterial Sinusitis
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Sep 2006
Shire Provides Update on U.S. Marketing Application of MESAVANCE(TM) (mesalamine) With MMX Technology
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 29 Aug 2006
FDA Advisory Committee Recommends Approval of Adeza's NDA for Gestiva to Prevent Preterm Birth
Biopharmaceuticals FDA
 HSMN NewsFeed - 28 Aug 2006
COLAZAL(R) Pediatric Exclusivity Granted
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 24 Aug 2006
Shire Announces NDA Submission of Guanfacine Extended Release for the Treatment of ADHD in Children and Adolescents
Biopharmaceuticals FDA
 HSMN NewsFeed - 14 Aug 2006
Shire and Barr Settle All Pending Litigation Concerning ADDERALL XR(R) and enter into Development and License Agreement
Biopharmaceuticals Generics Litigation Licensing
 HSMN NewsFeed - 14 Aug 2006
FDA Expands REMICADE(R) Psoriatic Arthritis Indication: Anti-TNF Shown to Inhibit Joint Damage and Improve Physical Function
Biopharmaceuticals FDA
 HSMN NewsFeed - 8 Aug 2006
Callisto Pharmaceuticals Announces Appointment of Robert C. Shepard, M.D., F.A.C.P., as Chief Medical Officer
Biopharmaceuticals Personnel
 HSMN NewsFeed - 2 Aug 2006
MoviPrep(R) Granted FDA Marketing Approval
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 24 Jul 2006
Shire's ELAPRASE(TM) (idursulfase) Approved by the Food and Drug Administration (FDA) for Hunter Syndrome
Biopharmaceuticals FDA
 HSMN NewsFeed - 20 Jul 2006
OVATION Pharmaceuticals Announces First New Drug Treatment in 20 Years for Premature Infants with Patent Ductus Arteriosus
Biopharmaceuticals Cardiology
 HSMN NewsFeed - 12 Jul 2006
Boston Scientific Launches Radial Jaw(R) 4, Newest Version of Single-Use Biopsy Forceps
Devices Gastroenterology
 HSMN NewsFeed - 10 Jul 2006
Prometheus Launches PROMETHEUS(R) IBD Serology 7
Diagnostics Gastroenterology
 HSMN NewsFeed - 5 Jul 2006
COLAZAL(R) Pediatric Exclusivity Filing Submitted
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 29 Jun 2006
sanofi-aventis Announces Update to Ketek(R) (Telithromycin) U.S. Prescribing Information
Biopharmaceuticals FDA
 HSMN NewsFeed - 29 Jun 2006
Shire's DAYTRANA(TM), First Transdermal Medication for Treatment of Attention Deficit Hyperactivity Disorder (ADHD) in Children, Now Available in Pharmacies
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 28 Jun 2006
Oscient Pharmaceuticals Announces Meeting Date for FDA Advisory Committee to Address sNDA for Five-Day Treatment of Acute Bacterial Sinusitis with FACTIVE Tablets
Biopharmaceuticals FDA
 HSMN NewsFeed - 22 Jun 2006
Advancis Pharmaceutical Signs Contract Sales Agreement With Innovex
Biopharmaceuticals
 HSMN NewsFeed - 21 Jun 2006
FDA Accepts REMICADE(R) Supplemental Biologics License Application for Inhibition of Structural Damage and Improving Physical Function in Patients With Psoriatic Arthritis
Biopharmaceuticals FDA
 HSMN NewsFeed - 5 Jun 2006
ENTOCORT(R) EC (budesonide) Capsules Recommended by the American Gastroenterology Association as First-Line Therapy for the Treatment of Mild-to-Moderate Crohn's Disease
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 5 Jun 2006
FDA Grants Adeza Priority Review for Gestiva to Prevent Preterm Births
Biopharmaceuticals FDA
 HSMN NewsFeed - 25 May 2006
Significant ADHD Symptom Control With Shorter DAYTRANA(TM) (methylphenidate transdermal system) Wear Time
Biopharmaceuticals
 HSMN NewsFeed - 24 May 2006
Positive Study Results for DAYTRANA(TM) (methylphenidate transdermal system) Presented at a Major Medical Meeting
Biopharmaceuticals Drug Delivery
 HSMN NewsFeed - 24 May 2006
New Analysis Showed Ulcerative Colitis Patients in Clinical Remission Had Higher Rates of Employment and Lower Rates of Disability
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 23 May 2006
Schering-Plough Initiates PEG-INTRON 'PROTECT' Study in Liver Transplant Patients with Recurrent Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 22 May 2006
New CIMZIA (TM) Data from PRECiSE Program Reinforce Robust Efficacy in Once-Monthly Treatment of Crohn's Disease and Consistent Tolerability Profile
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 22 May 2006
Study Reveals Zelnorm(R) May Be a Safe and Effective Treatment for Additional Group of IBS Patients With a Mixed Bowel Pattern
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 29 Apr 2006
PEGASYS(R) ACCELERATE Trial Shows Six Months of Treatment Is Optimal for Achieving Success in Category of Hepatitis C Patients
Biopharmaceuticals
 HSMN NewsFeed - 29 Apr 2006
New Oral Polymerase Inhibitor Shows Promising Results in Chronic Hepatitis C Patients
Biopharmaceuticals
 HSMN NewsFeed - 28 Apr 2006
UCB Submits Marketing Authorisation Application in Europe for CIMZIATM, a New Crohn's Disease Therapy
Biopharmaceuticals Regulatory Gastroenterology
 HSMN NewsFeed - 26 Apr 2006
EU Label Change for INTRON(R) A (interferon Alfa-2b) Incorporates Long-Term Efficacy Data in Patients with Chronic Hepatitis C
Biopharmaceuticals
 HSMN NewsFeed - 21 Apr 2006
FOSRENOL(r) Significantly Reduces Tablet Burden for End-Stage Renal Disease Patients With Hyperphosphatemia and Improves Patient and Physician Satisfaction, a New Study Reports
Biopharmaceuticals
 HSMN NewsFeed - 19 Apr 2006
Salix Announces Completion of OsmoPrep(TM) versus Liquid Bowel Cleanser Comparison Study
Biopharmaceuticals Gastroenterology
 HSMN NewsFeed - 6 Apr 2006
Shire's DAYTRANA(TM) Transdermal Patch Approved by FDA for Treatment of ADHD
Biopharmaceuticals FDA Drug Delivery
 HSMN NewsFeed - 4 Apr 2006
FDA Grants Priority Review of REMICADE(R) for the Treatment of Children with Active Crohn's Disease
Biopharmaceuticals Gastroenterology FDA
 HSMN NewsFeed - 29 Mar 2006
ViroPharma Announces Positive Phase 2 Results Demonstrating That Maribavir Significantly Reduces CMV Reactivation
Biopharmaceuticals
 HSMN NewsFeed - 23 Mar 2006
REMICADE(R) Is Approved in Australia for Treatment of Early Rheumatoid Arthritis and Psoriatic Arthritis
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 17 Mar 2006
OsmoPrep(TM) Tablets Granted FDA Marketing Approval
Biopharmaceuticals FDA
 HSMN NewsFeed - 10 Mar 2006
Shire Announces Status of Ongoing FDA Review of NDA for DAYTRANA(TM) for the Treatment of ADHD
Biopharmaceuticals FDA Drug Delivery
 HSMN NewsFeed - 9 Mar 2006
REMICADE(R) Is First Biologic Approved In European Union To Treat Ulcerative Colitis
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 6 Mar 2006
REMICADE(R) Phase 3 Data Show Rapid and Significant Improvement and Long-Term Response in the Treatment of Moderate to Severe Psoriasis
Biopharmaceuticals
 HSMN NewsFeed - 3 Mar 2006
REMICADE(R) Phase 3 Data Show Rapid and Significant Improvement and Long-Term Response in the Treatment of Moderate to Severe Psoriasis
Biopharmaceuticals Dermatology
 HSMN NewsFeed - 3 Mar 2006
Shire Sues Teva Pharmaceutical Industries Ltd. and Teva Pharmaceuticals USA, Inc.
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 2 Mar 2006
Wyeth Pharmaceuticals' Antibiotic TYGACIL Receives 'Positive Opinion' From European Regulatory Authority
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 21 Feb 2006
Cerimon Pharmaceuticals Licenses Exclusive Worldwide Rights to Simulect(R) for the Treatment of Inflammatory Bowel Disease
Biopharmaceuticals Licensing
 HSMN NewsFeed - 8 Feb 2006
Oscient Pharmaceuticals Acquires Expanded Worldwide Rights to Lead Clinical Candidate Ramoplanin
Biopharmaceuticals Licensing
 HSMN NewsFeed - 7 Feb 2006
FDA Grants Fast Track Status for ViroPharma's Maribavir for Prevention of Cytomegalovirus Infection
Biopharmaceuticals FDA
 HSMN NewsFeed - 3 Feb 2006
Shire Announces European Filings of SPD476 (Mesalazine) for Treatment of Ulcerative Colitis
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 30 Jan 2006
Schering-Plough Reports FDA Grants Fast Track Designation to Oral HCV Protease Inhibitor SCH 503034
Biopharmaceuticals FDA
 HSMN NewsFeed - 30 Jan 2006
European Union CHMP Recommends Approval of REMICADE(R) for Treatment of Moderately to Severely Active Ulcerative Colitis
Biopharmaceuticals Gastroenterology Regulatory
 HSMN NewsFeed - 20 Jan 2006
FDA Accepts for Filing Oscient Pharmaceuticals' Supplemental New Drug Application for Five-Day Treatment of CAP with FACTIVE(R) Tablets, Refuses Filing for Five-Day Treatment of ABS
Biopharmaceuticals FDA
 HSMN NewsFeed - 19 Jan 2006
Shire and Impax Settle all Pending Litigation Concerning ADDERALL XR(R)
Biopharmaceuticals Generics Litigation
 HSMN NewsFeed - 19 Jan 2006
ViroPharma Broadens Senior Management
Biopharmaceuticals Personnel
 HSMN NewsFeed - 18 Jan 2006
ADDERALL XR(R) - Paragraph IV Notice Update - Third Notice Letter From Teva Pharmaceuticals USA, Inc.
Biopharmaceuticals Generics
 HSMN NewsFeed - 13 Jan 2006
Schering-Plough Initiates PEG-INTRON(R) Maintenance Study in Patients Coinfected With Hepatitis C and HIV
Biopharmaceuticals HIV/AIDS
Return to NewsFeed  

 Additional items found! 165

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 165 additional stories matching:
colitis
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.